Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,502,322
  • Shares Outstanding, K 166,045
  • Annual Sales, $ 2,181 M
  • Annual Income, $ 151,000 K
  • 60-Month Beta 0.10
  • Price/Sales 3.04
  • Price/Cash Flow 19.28
  • Price/Book 3.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.28
  • Growth Rate Est. (year over year) +356,685.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.18 +10.61%
on 03/01/19
40.84 -2.01%
on 03/20/19
+2.65 (+7.09%)
since 02/25/19
3-Month
35.50 +12.73%
on 02/15/19
40.84 -2.01%
on 03/20/19
+2.95 (+7.96%)
since 12/24/18
52-Week
28.13 +42.27%
on 05/21/18
40.84 -2.01%
on 03/20/19
+8.09 (+25.34%)
since 03/23/18

Most Recent Stories

More News
Top Ranked Momentum Stocks to Buy for March 20th

Top Ranked Momentum Stocks to Buy for March 20th

GNCA : 0.61 (-8.65%)
CLAR : 11.80 (+1.11%)
RDY : 40.02 (+2.20%)
SIC : 11.71 (-3.22%)
Factors of Influence in 2019, Key Indicators and Opportunity within Vanda Pharmaceuticals, Range Resources, Fortune Brands Home & Security, Dr. Reddy's Laboratories, BWX Technologies, and K12 -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Vanda Pharmaceuticals Inc....

RRC : 10.97 (+0.92%)
RDY : 40.02 (+2.20%)
FBHS : 45.51 (+1.11%)
LRN : 33.20 (+1.84%)
VNDA : 17.76 (+0.97%)
BWXT : 48.51 (+0.89%)
Dr. Reddy's Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation

Dr. Reddy's Laboratories Ltd. ((BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) along with its subsidiaries together referred to as "Dr. Reddy's") announced today the re-launch of its Buprenorphine...

RDY : 40.02 (+2.20%)
Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Tadalafil Tablets USP,...

RDY : 40.02 (+2.20%)
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3

Dr. Reddy's earnings and sales rise year over year in the third-quarter of fiscal 2019.

RDY : 40.02 (+2.20%)
VYGR : 19.14 (+6.51%)
MNK : 21.62 (-2.13%)
ZYNE : 5.72 (-1.04%)
Dr. Reddy's Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as "Dr. Reddy's") today announced the appointment of Marc Kikuchi as...

RDY : 40.02 (+2.20%)
Dr. Reddy's (RDY) Earnings Rise in Q3, Sales Increase Y/Y

Dr. Reddy???s earnings and sales increase year over year in the third quarter of fiscal 2019.

RDY : 40.02 (+2.20%)
Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?

Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.

RDY : 40.02 (+2.20%)
AGN : 146.34 (-1.98%)
LLY : 129.87 (+1.22%)
BHC : 24.14 (-2.23%)
Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Propofol Injectable Emulsion,...

RDY : 40.02 (+2.20%)
Dr. Reddy's to Release Q3 FY19 Results on February 1, 2019

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the quarter ended December 31, 2018 on Friday, February 1, 2019 after the Board Meeting.

RDY : 40.02 (+2.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade RDY with:

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Key Turning Points

2nd Resistance Point 40.85
1st Resistance Point 40.43
Last Price 40.02
1st Support Level 39.60
2nd Support Level 39.19

See More

52-Week High 40.84
Last Price 40.02
Fibonacci 61.8% 35.98
Fibonacci 50% 34.49
Fibonacci 38.2% 32.99
52-Week Low 28.13

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar